MXPA96002972A - (tiofen-2-il) piperidin or tetrahidropiridin azabiciclocarboxami - Google Patents

Abstract

This invention provides compounds having the structure (I), wherein: R is hydrogen, alkyl, alkenyl, alkynyl, -COR2, phenyl or phenylalkyl, the dotted line represents an optional double bond, R1 is hydrogen, -OH, OR3, or is absent if the double bond is present, R2 and R3 are each independently alkyl, alkenyl, alkynyl, phenyl or phenylalkyl, R4 is hydrogen, OR5, alkyl, alkenyl, alkynyl, -COR5, -CO2R5, - CONR5R6, perhaloalkyl, halogen, phenyl or phenylalkyl, R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkynyl, phenyl or phenylalkyl, and n = 0a2 or a pharmaceutically acceptable salt thereof, which are useful as agents antipsychotics, antidepressants and anxiolytics, useful in the treatment and relief of the symptoms of these conditions

Description

(TI0FEN-2-ID-PIPBRIDIN OR TETRAHIDROPIRIDIN AZABICICLOCARBOXAMIDAS This invention provides compounds having selectivity for the serotonergic receptor 5-HT,, useful in the treatment of diseases of the central nervous system, which has the structure: wherein: R is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, -COR, phenyl or phenylalkyl of 7 to 10 carbon atoms; the dotted line represents a double bond, optional; R 1 is hydrogen, -OH, OR 3, or is absent if the optional double bond is present; R 2 and R 3 are each, independently, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 atoates REF: 22750 carbon, alkynyl of 2 to 7 carbon atoms, phenyl or phenylalkyl of 7 to 10 carbon atoms; 4, 5 R is hydrogen, -OR, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, -COR 5, -C02R5, -CONR5R6, perhaloalkyl of 1 to 6 carbon atoms, halogen, phenyl or phenylalkyl of 7 to carbon atoms; R and R are each, independently, hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenyl or phenylalkyl of 7 to 10 carbon atoms. carbon; and n = 0 to 2 or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salts are those derived from organic and inorganic acids, such as acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic and the like, known, acceptable acids . The terms alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms and alkynyl of 2 to 7 carbon atoms include both straight and branched carbon chains. In the generic structure described above, when n = 0 the ring containing sulfur is a thiophene ring, when n = 1 the ring containing sulfur is a thiophene S-oxide and when n = 2 the ring containing sulfur is a S-thiophene dioxide. The term "halogen" refers to fluorine, chlorine, bromine or iodine. The compounds within the scope of the invention, by virtue of their configuration, exhibit stereoisomerism. These centers may contain either R or S configuration, or may be racially related to this center, or centers. Accordingly, the compounds of the invention include the diastereomers, enantiomers, racemates and mixtures thereof. Of these compounds, the preferred members are those in which n = 0, and in which n = 0 and R is alkyl of 1 to 6 carbon atoms. The compounds of this invention can be prepared by conventional methods. For example, the 2-bromo-thiophene, suitably substituted, can be subjected to a Grignard reaction, in which addition to a 4-piperidone carbamate provides the desired tertiary alcohol. Subsequent hydrolysis of the carbamate gives the desired 4-hydroxy-4-thiophen-2-yl-piperidine, as shown in scheme 1. (1) The piperidine substituted at position 4 is subjected to a reductive amination, using substituted butyraldehyde, in the presence of sodium borocyanohydride, to give the final products, as illustrated in scheme 2, The subsequent functionalization of the hydroxyl group of piperidine can be carried out using standard methodology; and dehydration of the hydroxyl group, to provide tetrahydropyridine derivatives, may be carried out under mildly acidic conditions. Representative compounds of this invention were evaluated and determined to possess a high affinity for the serotonin 5-HT receptor, evaluating the ability of the compound to displace the (H) 8-OHDPAT (dipropylaminotetralin) of the serotonin 5-HT receptor. , following the procedure of Hall et al., J Neurochem. 44, 1685 (1985). This standard pharmacological evaluation procedure was used to observe the analogy of this property of the claimed compounds with that of the buspirone., which is a standard for anxiolytic activity and, like the compounds of this invention, has a potent affinity for the serotonin receptor of the 5-HT subtype. It is thought that the anxiolytic activity of buspirone is due, at least partially, to its affinity for the 5-HT receptor, (Vander Maclen et al., Eur. J. Pharmacol., 1986, 129. (1-2) 133- 130). In this standard pharmacological test procedure, buspirone has an IC5Q of approximately 10 nM. The results obtained for the representative compounds of this invention, in the standard pharmacological evaluation procedure, described above are as follows: Compound Union to 5-HT- ,. (IC5Q) Example 1 942 nM Example 2 0.9 nM The results obtained in the standard pharmacological evaluation procedure demonstrate that the compounds of this invention possess high affinities for the serotonin 5-HT receptor. and, consequently, they are useful in the treatment of multi-CNS diseases, which are subject to treatment with antipsychotic, antidepressant and anxiolytic agents. As such, the compounds of this invention can be administered, to a mammal in need of medical antipsychotic, antidepressant and / or anxiolytic treatment, in an amount sufficient to alleviate the symptoms of the disease state, such as depression, paranoia, schizophrenia, anxiety. , sleep disorders, eating disorders, cognitive disorders, panic, social phobia, obsessive compulsive disorders, sexual dysfunction, addiction and related problems. When administered for the treatment of the disease states mentioned above, the compounds of this invention can be administered to a mammal orally, parenterally, intranasally, intrabronchially, transdermally, intravaginally or rectally. The compounds of this invention can be formulated, either pure or with a pharmaceutical carrier, for a mammal in need thereof. The pharmaceutical carrier can be solid or liquid. A solid carrier may include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, slip agents, compression aids, binders or tablet disintegrating agents; It can also be an encapsulating material. In the powders, the vehicle is a finely divided solid that is mixed with the active ingredient, finely divided. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the desired shape and size. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatins, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinyl pyrrolidine, low melting point waxes and resins of ion exchange Liquid vehicles are used to prepare solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier, such as water, an organic solvent, a mixture of oils or fat, pharmaceutically acceptable. The liquid carrier may contain other pharmaceutically suitable additives, such as solubilizers, emulsifiers, pH buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (which partially contains additives, such as those mentioned above, eg, cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, eg, glycols) and their derivatives, and oils (eg, fractionated coconut oil and peanut oil). For parenteral administration the carrier can also be a fatty ester, such as oleate is ethyl and isopropyl myristate. Sterile liquid carriers are useful in liquid, sterile compositions for parenteral administration. The liquid carrier, for pressurized compositions, may be halogenated hydrocarbon or other pharmaceutically acceptable propellant.

Liquid pharmaceutical compositions that are sterile solutions or suspensions can be used, for example, by intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compound can also be administered orally, either in the form of a liquid or solid composition. The compounds of this invention can be administered rectally, in the form of a conventional suppository. For administration by intranasal or intrabronchial inhalation or insufflation, the compounds of this invention can be formulated in an aqueous, or partially aqueous solution, which can then be used in the form of an aerosol. The compounds of this invention can also be administered transdermally, by the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is not toxic to the skin and allows the distribution of the agent for systemic absorption towards the skin. bloodstream, via the skin. The vehicle can take any number of forms, such as creams and ointments, pastes, gels and occlusive devices. The creams and ointments can be liquid, viscous or semi-solid emulsions, of the oil-in-water or water-in-oil type. Pastes, which are composed of absorptive powders, dispersed in petroleum, or in hydrophilic petroleum containing the active ingredient, may also be suitable. A variety of occlusive devices can be used to release the active ingredient into the bloodstream, such as a semi-permeable membrane, which covers a reservoir containing the active ingredient, with or without a vehicle or matrix containing the active ingredient. Other occlusive devices are known in the literature. The dose to be used in the treatment of a specific psychosis must be determined subjectively by the attending physician. The variables involved include the specific psychosis, or state of anxiety or depression, and the patient's size, age, and response pattern. Based on the results obtained in the standard pharmacological evaluation procedures, the projected oral daily doses of the active compound would be from 1 to 100 mg / Kg, preferably from 1 to 30 mg / Kg and, more preferably, from 1 to 10 mg /. Kg. The projected intravenous daily doses would be from 0.2 to 20 mg / Kg, preferably from 0.2 to 6 mg / Kg, and more preferably from 0.2 to 2 mg / Kg. The treatment will begin, in general, with small doses, less than the optimum dose of the compound. Subsequently, the dose is increased until the optimum effect is reached under the circumstances; The precise doses for oral, parenteral, nasal or intrabronchial administration will be determined by the physician administering the compound, based on the experience with the individual subject treated. Preferably, the pharmaceutical composition is in dosage unit form, e.g., as tablets or capsules. In this form, the composition is subdivided into a dosage unit that contains adequate amounts of the active ingredient; Dosage unit forms may be packaged compositions, for example, powders, packages, vials, ampoules, pre-filled syringes or pads containing liquids. The dosage unit form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any of the compositions in package form. The following examples illustrate the production of the representative compounds of this invention.

Preparation of (R) -4- (8-aza-bicyclo (3.2.1.) Oct-8-yl) -4-oxo-3- * phenyl-butyraldehyde or (R) -2-phenyl-4- acid The initial pentenoic can be prepared according to the procedure of Cervinka et al .: Collect. Czech Chem. Commun. (1967), 32 (6), 2295-300. The nortropane reagent was prepared according to established methods, e.g., J. Org. Chem., (1984), 49,2081-2. Under dry nitrogen, and protected from light, 1-hydroxybenztriazole (0.46 g, 2.84 mmol) was added to a solution of the initial (R) -2-phenyl-4-pentenoic acid (0.5 g, 2.84 mmol) in methylene chloride. (5 mL), at room temperature, followed by the addition of a solution of l- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.54 g, 2.84 mmol) in methylene chloride (20 mL). The reaction mixture was stirred for 2 hours, after which a solution of nortropane (0.32 g, 2.84 mmol) in methylene chloride (5 mL) was added dropwise and stirring was continued at room temperature throughout the night. The solvent was removed under vacuum, at room temperature, and the residue was partitioned between ethyl acetate (20 mL) and IN hydrochloric acid (20 mL). The separated organic layer was washed with water (4 x 20 mL), brine (2 x 20 mL), dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to give the desired crude compound (R) -l- (8-aza-bicyclo (3.2.1.) Oct-8-yl) -2-phenyl-pent-4-en-1-one. , which can be purified by flash chromatography on 60 g of silica gel using 35% ethyl acetate / hexane as eluent. The material (0.5 g, 1.86 mmol) was dissolved in a mixture of tetrahydrofuran (13 mL) and water (4 mL) and stirred under nitrogen. Osmium tetroxide (0.37 mL, 0.03 equivalents, as a 4% aqueous solution) was added, followed by an addition, in the form of portions, of sodium periodate (1.19 g, 5.56 mmol). After stirring at room temperature for 1 hour, water (10 mL), ethyl acetate (20 mL), and brine (10 mL) were added to the reaction mixture. The organic layer was separated, washed with brine (2 x 20 mL), dried over magnesium sulfate, and filtered. The filtrate was evaporated in vacuo. Flash column chromatography of the residue on 52 g of silica gel with 50% ethyl acetate / hexane as eluent followed by crystallization from ether / hexane gave 0.29 g of the title compound, m.p. 82-5 C.

EXAMPLE 1 Hydrochloride of (R) -l- (8-aza-bicyclo (3.2.1.) Oct-8-yl) -4- (4-hydroxy-4- (3-methoxy-thiophen-2-yl) -piperidine- 1-yl) -2-phenyl-butan-1-one. Acetic acid (0.48 mL) was added to a solution of 4-hydroxy-4-thiophen-2-yl-piperidine (0.853 g, 4 mmol) and (R) -4- (Initial 8-aza-bicyclo (3.2.1.) Oct-8-yl) -4-oxo-3-phenyl-butyraldehyde (1.085 g, 4 mmol), in methanol (30 mL), a room temperature. Subsequently, sodium cyanoborohydride (0.276 g, 4.4 mmol) was added in a single addition, and the reaction mixture was stirred at room temperature for 3 hours. The mixture was vacuum in 10% aqueous sodium bicarbonate (60 mL) and extracted with methylene chloride (3 x 50 mL). The organic extracts were combined, washed with water (50 mL), brine (50 mL), dried over magnesium sulfate and filtered. The filtrate was evaporated in vacuo and the residue was dissolved in chloroform (50 mL). Ethanolic hydrochloric acid was added and the resulting solution was evaporated. The residue was triturated in ether and the precipitate was filtered and dried to give 1.8 g of the title compound, m.p. 106-8 ° C.

Elemental analysis for: C-.7H-gN_O-S.HCl. Calculated: C, 64.20; H, 7.38; N, 5.55. Found: C, 64.08; H, 7.57; N, 5.40.

EXAMPLE 2 Hemi-hydrochloride of (R) -l- (8-aza-bicyclo (3.2.1.) Oct-8-yl) -4- (4- (3-ratoxy-thiophen-2-yl) -1, 2, 3, 6-tetrahydro-pyridin-l-yl) -2-phenyl-butan-1-one Hydrochloride of (R) -l- (8-aza-bicyclo (3.2.1.) Oct-8-yl) - 4- (4-hydroxy-4- (3-methoxy-thiophen-2-yl) -piperidin-1-yl) -2-phenyl-butan-1-one initial (Example 1, 1.17 g, 3.6 mmol), dissolved in acetic acid (80 mL) and heated to a bath temperature of 140 ° C for 2% hours. Subsequently the reaction mixture was stirred at room temperature overnight, evaporated to dryness in vacuo and the residue was partitioned between 5% aqueous sodium bicarbonate (50 mL) and chloroform (2 x 100 mL). The combined organic layer was separated, dried over magnesium sulfate, filtered and evaporated to dryness in vacuo. Flash column chromatography, on 100 g of silica gel, with 3% methanol / chloroform, as eluent, followed by crystallization from ethanol / ether, with the addition of ethanolic hydrochloric acid, gives 0.7 g of the title compound, pf 100-3 ° C Elemental analysis for: C27H3.N202S.l.5HC1.

Calculated: C, 64.17; H, 7.08; N, 5.54. Found: C, 64.02; H, 6.94; N, 5.32.

It is noted that, in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is the conventional one for the manufacture of the objects or products to which it refers. Having described the invention as above, the content of the following is claimed as property.

Claims (9)

1. A compound characterized in that it is represented by the structure: where R is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, -COR 2, phenyl or phenylalkyl of 7 to 10 carbon atoms; the dotted line represents an optional double bond; R 1 is hydrogen, -OH, OR 3, or is absent if the double bond is present; R 2 and R 3 are each, independently, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenyl or phenylalkyl of 7 to 10 carbon atoms; R 4 is hydrogen, OR 5, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, -COR 5, -C02R 5, -CONR 5 R 6, perhaloalkyl of 1 to 6 carbon atoms, halogen, phenyl or phenylalkyl of 7 to 10 carbon atoms; R and R are each, independently, hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenyl, or phenylalkyl of 7 to 10 atoms of carbon; and n = 0 to 2 or a pharmaceutically acceptable salt thereof.

2. The compound, according to claim 1, characterized in that n = 0, or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2, characterized in that R is alkyl of 1 to 6 carbon atoms, or a pharmaceutically acceptable salt thereof.

4. The compound, according to claim 1, characterized in that it is (R) -l- (8-aza-bicyclo (3.2.1.) Oct-8-yl) -4- (4-hydroxy-4- (3- methoxy-thiophen-2-yl) -piperidin-1-yl) -2-phenyl-butan-1-one or a pharmaceutically acceptable salt thereof.

5. The compound, according to claim 1, characterized in that it is the hydrochloride salt of the - - (R) -l- (8-aza-bicyclo (3.2.1.) Oct-8-yl) -4- (4-hydroxy-4- (3-methoxy-thiophen-2-yl) -piperidine-l- il) -2-phenyl-butan-1-one.

6. The compound according to claim 1, characterized in that it is the (R) -l- (8-aza-bicyclo (3.2.1.) Oct-8-yl) -4- (4- (3-methoxy-thiophene) -2-yl) -1, 2, 3, 6-tetrahydro-pyridin-1-yl) -2-phenyl-butan-1-one or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1, characterized in that it is the hemi-hydrochloride of (R) -l- (8-aza-bicyclo (3.2.1.) Oct-8-yl) -4- (4- (3 -methoxy-thiophen-2-yl) -l, 2,3,6-tetrahydro-pyridin-1-yl) -2-phenyl-butan-1-one.

8. Use of a compound of the structure shown below for the treatment of anxiety, psychosis, or depression, to administer to the mammal an effective amount: - - wherein R is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, -COR 2, phenyl or phenylalkyl of 7 to 10 carbon atoms; the dotted line represents an optional double bond; R 1 is hydrogen, -OH, OR 3, or is absent if the double bond is present; R 2 and R 3 are each, independently, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenyl or phenylalkyl of 7 to 10 carbon atoms; R 4 is hydrogen, OR 5, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 acccc 7 carbon atoms, -COR, -CO-R, -CONR R, perhaloalkyl of 1 to 6 carbon atoms, halogen, phenyl or phenylalkyl of 7 to 10 carbon atoms; R and R are each, independently, hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenyl, or phenylalkyl of 7 to 10 atoms of carbon; and n = 0 to 2 or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition characterized in that it comprises - - a co-tax that is represented by the structure where R is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, -COR 2, phenyl or phenylalkyl of 7 to 10 atoms-of carbon; the dotted line represents an optional double bond; R 1 is hydrogen, -OH, OR 3, or is absent if the double bond is present; R 2 and R 3 are each, independently, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenyl or phenylalkyl of 7 to 10 carbon atoms; R 4 is hydrogen, OR 5, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 acccc 7 carbon atoms, -COR, -CO-R, -CONR R, perhaloalkyl of 1 to 6 carbon atoms, halogen, phenyl or phenylalkyl of 7 to 10 carbon atoms; R and R are each, independently, hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 7 carbon atoms, alkynyl of 2 to 7 carbon atoms, phenyl, or phenylalkyl of 7 to 10 atoms of carbon; and n = 0 to 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier. SUMMARY OF THE INVENTION This invention provides compounds that have the structure where 2 R is hydrogen, alkyl, alkenyl, alkynyl, -COR, phenyl or phenylalkyl; the dotted line represents an optional double bond; R 1 is hydrogen, -OH, OR 3, or is absent if the double bond is present; R 2 and R 3 are each independently alkyl, alkenyl, alkynyl, phenyl or phenylalkyl; R 4 is hydrogen, OR 5, alkyl, alkenyl, alkynyl, -COR, -C02R, -CONR R, perhaloalkyl, halogen, phenyl or phenylalkyl; R and R are each, independently, hydrogen, alkyl, alkenyl, alkynyl, phenyl, or phenylalkyl; and n = 0 to 2 or a pharmaceutically acceptable salt thereof, which are useful as antipsychotic, antidepressant and anxiolytic agents, useful in the treatment and alleviation of the symptoms of these disease states.